MTSR Metsera, Inc. Common Stock

$33.05

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Metsera, Inc. Common Stock

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. The company is headquartered in New York, New York.

Website: https://metsera.com

Sector
TECHNOLOGY
Industry
GENERAL
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
nan
Address
NONE
Valuation
Market Cap
$3.09B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
0.00
Performance
EPS
$nan
Dividend Yield
—
Profit Margin
0.00%
ROE
0.00%
Technicals
50D MA
$28.43
200D MA
$28.43
52W High
$32.81
52W Low
$12.30
Fundamentals
Shares Outstanding
15M
Target Price
$nan
Beta
nan

MTSR EPS Estimates vs Actual

● Estimated
● Actual

MTSR News & Sentiment

Jul 28, 2025 • Zacks Commentary BULLISH
Recent Price Trend in Metsera Inc. ( MTSR ) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Metsera Inc. (MTSR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Jul 28, 2025 • Benzinga NEUTRAL
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - ATAI Life Sciences ( NASDAQ:ATAI ) , Cantor Equity Partners I ( NASDAQ:CEPO )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday. Shares of ATAI Life Sciences NV ATAI fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with ...
Jul 10, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Wall Street Analysts See a 55.72% Upside in Metsera Inc. ( MTSR ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Jul 10, 2025 • Benzinga NEUTRAL
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - BitMine Immersion Techs ( AMEX:BMNR ) , Altimmune ( NASDAQ:ALT )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI fell sharply in today's pre-market trading after the company reported a fourth-quarter adjusted EPS miss.
Jul 01, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Nasdaq Welcomes 142 IPOs in the First Half of 2025
Highest volume of listings and capital raise in the first half of the year since ...
Jul 01, 2025 • Business Insider SOMEWHAT-BULLISH
Nasdaq Welcomes 142 IPOs in the First Half of 2025
Nasdaq Welcomes 142 IPOs in the First Half of ...
Sentiment Snapshot

Average Sentiment Score:

0.102
26 articles with scored sentiment

Overall Sentiment:

Neutral

MTSR Reported Earnings

Mar 26, 2025
Dec 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.50
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%

Financials